Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1NET 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoid Tumor 1Adrenal Cortex Neoplasms 1

Interventions

telotristat ethyl 3lutetium Lu 177 dotatate 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vandetanib 1pasireotide 1gallium Ga 68 dotatate 1Tretinoin 1Temozolomide 1Isotretinoin 1Introns 1Everolimus 1Diazoxide 1Capecitabine 1177Lu-octreotate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × veliparib × NET × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡